BRPI0614964A2 - método para a modulação de crescimento neoplástico, uso de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, uso de um anibidor de via de sinalização de egfr, formulação farmacêutica, e, kit - Google Patents

método para a modulação de crescimento neoplástico, uso de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, uso de um anibidor de via de sinalização de egfr, formulação farmacêutica, e, kit

Info

Publication number
BRPI0614964A2
BRPI0614964A2 BRPI0614964A BRPI0614964A BRPI0614964A2 BR PI0614964 A2 BRPI0614964 A2 BR PI0614964A2 BR PI0614964 A BRPI0614964 A BR PI0614964A BR PI0614964 A BRPI0614964 A BR PI0614964A BR PI0614964 A2 BRPI0614964 A2 BR PI0614964A2
Authority
BR
Brazil
Prior art keywords
prodrug
kit
ester
compound
pharmaceutically acceptable
Prior art date
Application number
BRPI0614964A
Other languages
English (en)
Inventor
Colin Green
Gail Rowlinson-Busza
Lloyd Kelland
Original Assignee
Antisoma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Plc filed Critical Antisoma Plc
Publication of BRPI0614964A2 publication Critical patent/BRPI0614964A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

compressor. a presente invenção se refere a compressores (1) que compreendem um pé (60, 600), facilitando sua montagem no dispositivo em que ele será utilizado. no referido compressor (1), além dos furos de fixação (71, 72, 701, 702), um furo auxiliar adjacente (81, 82, 801, 802) é formado a fim de se encaixar facilmente na gaxeta (3) que atenua as vibrações.
BRPI0614964A 2005-08-26 2006-08-25 método para a modulação de crescimento neoplástico, uso de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, uso de um anibidor de via de sinalização de egfr, formulação farmacêutica, e, kit BRPI0614964A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517387.7A GB0517387D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
PCT/GB2006/003207 WO2007023307A1 (en) 2005-08-26 2006-08-25 Combinations comprising dmxaa for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0614964A2 true BRPI0614964A2 (pt) 2016-09-13

Family

ID=35198384

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614964A BRPI0614964A2 (pt) 2005-08-26 2006-08-25 método para a modulação de crescimento neoplástico, uso de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, uso de um anibidor de via de sinalização de egfr, formulação farmacêutica, e, kit

Country Status (16)

Country Link
US (1) US20100104565A1 (pt)
EP (1) EP1931331A1 (pt)
JP (1) JP2009506020A (pt)
KR (1) KR20080048488A (pt)
CN (1) CN101296695A (pt)
AU (1) AU2006283376A1 (pt)
BR (1) BRPI0614964A2 (pt)
CA (1) CA2620447A1 (pt)
EC (1) ECSP088242A (pt)
GB (1) GB0517387D0 (pt)
IL (1) IL189377A0 (pt)
MA (1) MA29784B1 (pt)
NO (1) NO20080650L (pt)
RU (1) RU2404765C2 (pt)
TN (1) TNSN08057A1 (pt)
WO (1) WO2007023307A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd COMBINED TREATMENT AGAINST CANCER
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US8287346B2 (en) * 2008-11-03 2012-10-16 Cfph, Llc Late game series information change
US20160287623A1 (en) * 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
MA29784B1 (fr) 2008-09-01
CA2620447A1 (en) 2007-03-01
GB0517387D0 (en) 2005-10-05
KR20080048488A (ko) 2008-06-02
RU2404765C2 (ru) 2010-11-27
RU2008111493A (ru) 2009-10-10
IL189377A0 (en) 2008-06-05
WO2007023307A1 (en) 2007-03-01
TNSN08057A1 (en) 2009-07-14
AU2006283376A1 (en) 2007-03-01
ECSP088242A (es) 2008-08-29
CN101296695A (zh) 2008-10-29
US20100104565A1 (en) 2010-04-29
JP2009506020A (ja) 2009-02-12
EP1931331A1 (en) 2008-06-18
NO20080650L (no) 2008-05-13

Similar Documents

Publication Publication Date Title
UY28369A1 (es) Agentes terapéuticos
DOP2009000257A (es) Inhibidores de cinasa p70 s6
BRPI0519349A8 (pt) Prevenção de formação e/ou estabilização de trombos
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
ECSP088296A (es) Compuestos terapéuticos
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
GT200500269A (es) Procedimiento
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
UY29061A1 (es) Procedimiento para la preparación de dihidropteridinonas
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
AR063188A1 (es) Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
BRPI0515776A (pt) auxiliares de retenção e drenagem
CR7999A (es) Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero
CR20130666A (es) Composición de emulsión estable (divisional expediente 9495)
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
UY30460A1 (es) Compuestos terapéuticos
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
ECSP077270A (es) Ácidos de tiazolo - naftilo
EP1668116A4 (en) METHOD FOR IMPROVING EMBRYOVIABILITY
MX2007009032A (es) Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales.
BRPI0512622A (pt) uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor
BRPI0614964A2 (pt) método para a modulação de crescimento neoplástico, uso de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, uso de um anibidor de via de sinalização de egfr, formulação farmacêutica, e, kit

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20080028602/RJ DE 27/02/2008.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: ANTISOMA PLC (GB)